Alice Lhabouz, CE and founder of Trecento AM, comments on Challenges news from the Swiss giant Novartis, and also the announcement of Varant Narasimhan, CEO of the company since February.
« The group will focus on specialty pharma, personalized medicine and rare diseases with growth and higher margins, enough to reallocate capital and increase the (…) »
Read the article by clicking here (available in French only)